Last updated: 15:31
No Notes Added Yet
Infinium Pharmachem Ltd is a dynamic and innovative company operating in the pharmaceutical and chemical industry. With a commitment to excellence and a focus on customer satisfaction, Infinium Pharmachem has established itself as a trusted provider of high-quality products and services. The company specializes in the manufacturing and distribution of a wide range of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and fine chemicals. Leveraging state-of-the-art technology and a team of experienced professionals, Infiniu...Read More
Infinium Pharmachem Ltd is a dynamic and innovative company operating in the pharmaceutical and chemical industry. With a commitment to excellence and a focus on customer satisfaction, Infinium Pharmachem has established itself as a trusted provider of high-quality products and services. The company specializes in the manufacturing and distribution of a wide range of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and fine chemicals. Leveraging state-of-the-art technology and a team of experienced professionals, Infinium Pharmachem strives to meet the evolving needs of its clients. Infinium Pharmachem is dedicated to maintaining the highest standards of quality, safety, and environmental sustainability in its operations. The company adheres to stringent regulatory guidelines and continuously invests in research and development to deliver innovative solutions and products. With a global presence and a strong network of partners, Infinium Pharmachem aims to contribute to the advancement of the pharmaceutical and chemical sectors, while fostering long-term relationships with its customers and stakeholders. ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹337 Cr.
Stock P/E 43
P/B 3.1
Current Price ₹216.3
Book Value ₹ 70.2
Face Value 10
52W High ₹337
Dividend Yield 0%
52W Low ₹ 189.4
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) |
|---|
| Net Sales |
| Other Income |
| Total Income |
| Total Expenditure |
| Operating Profit |
| Interest |
| Depreciation |
| Exceptional Income / Expenses |
| Profit Before Tax |
| Provision for Tax |
| Profit After Tax |
| Adjustments |
| Profit After Adjustments |
| Adjusted Earnings Per Share |
| #(Fig in Cr.) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Net Sales | 39 | 71 | 99 | 114 | 136 | 156 | |
| Other Income | 1 | 1 | 1 | 1 | 2 | 2 | |
| Total Income | 39 | 71 | 100 | 116 | 137 | 158 | |
| Total Expenditure | 36 | 66 | 89 | 98 | 117 | 139 | |
| Operating Profit | 3 | 6 | 11 | 17 | 20 | 19 | |
| Interest | 1 | 1 | 2 | 3 | 2 | 4 | |
| Depreciation | 1 | 1 | 1 | 1 | 3 | 3 | |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | |
| Profit Before Tax | 1 | 4 | 9 | 13 | 15 | 12 | |
| Provision for Tax | 0 | 1 | 2 | 3 | 4 | 4 | |
| Profit After Tax | 1 | 3 | 7 | 10 | 12 | 8 | |
| Adjustments | 0 | -0 | -1 | -0 | -0 | 0 | |
| Profit After Adjustments | 1 | 3 | 6 | 9 | 11 | 8 | |
| Adjusted Earnings Per Share | 0.9 | 2.7 | 6 | 9.3 | 8.1 | 5.2 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 15% | 16% | 32% | 0% |
| Operating Profit CAGR | -5% | 20% | 45% | 0% |
| PAT CAGR | -33% | 5% | 52% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -27% | 27% | NA% | NA% |
| ROE Average | 9% | 31% | 42% | 38% |
| ROCE Average | 13% | 26% | 30% | 28% |
| #(Fig in Cr.) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Shareholder's Funds | 4 | 7 | 13 | 23 | 59 | 109 |
| Minority's Interest | 0 | 0 | 1 | 1 | 1 | 15 |
| Borrowings | 6 | 6 | 14 | 10 | 8 | 10 |
| Other Non-Current Liabilities | -0 | -0 | -0 | -0 | -0 | -0 |
| Total Current Liabilities | 12 | 21 | 31 | 37 | 17 | 64 |
| Total Liabilities | 22 | 34 | 59 | 71 | 85 | 198 |
| Fixed Assets | 4 | 5 | 4 | 19 | 20 | 24 |
| Other Non-Current Assets | 0 | 4 | 11 | 0 | 1 | 34 |
| Total Current Assets | 18 | 25 | 44 | 51 | 65 | 140 |
| Total Assets | 22 | 34 | 59 | 71 | 85 | 198 |
| #(Fig in Cr.) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 1 | 2 | 5 | 6 | 12 |
| Cash Flow from Operating Activities | 3 | 7 | 12 | 9 | 5 | -29 |
| Cash Flow from Investing Activities | -1 | -5 | -7 | -5 | -4 | -27 |
| Cash Flow from Financing Activities | -1 | -1 | -2 | -3 | 5 | 79 |
| Net Cash Inflow / Outflow | 1 | 1 | 3 | 1 | 6 | 23 |
| Closing Cash & Cash Equivalent | 1 | 2 | 5 | 6 | 12 | 35 |
| # | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 0.92 | 2.68 | 6.01 | 9.33 | 8.12 | 5.23 |
| CEPS(Rs) | 1.43 | 3.33 | 7.2 | 10.97 | 10.18 | 7.15 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 4.18 | 6.91 | 12.89 | 22.19 | 42.24 | 70.25 |
| Core EBITDA Margin(%) | 6.39 | 7.02 | 10.12 | 14.05 | 13.66 | 10.58 |
| EBIT Margin(%) | 6.38 | 6.98 | 10.43 | 14.06 | 12.83 | 9.83 |
| Pre Tax Margin(%) | 3.19 | 5.34 | 8.71 | 11.34 | 11.21 | 7.43 |
| PAT Margin (%) | 2.23 | 3.87 | 6.75 | 8.59 | 8.48 | 5.04 |
| Cash Profit Margin (%) | 3.73 | 4.79 | 7.38 | 9.77 | 10.45 | 7.15 |
| ROA(%) | 3.87 | 9.66 | 14.37 | 15.16 | 14.75 | 5.53 |
| ROE(%) | 20.43 | 48.44 | 66.44 | 55.06 | 28.28 | 9.32 |
| ROCE(%) | 18.89 | 32.14 | 38.88 | 36.74 | 28.57 | 13.23 |
| Receivable days | 74.56 | 50.25 | 49.49 | 49.25 | 48.28 | 63.52 |
| Inventory Days | 64.85 | 42.14 | 47.4 | 57.64 | 59.75 | 80.81 |
| Payable days | 82.28 | 62.12 | 28.25 | 0 | 0 | 0 |
| PER(x) | 0 | 0 | 0 | 0 | 28.2 | 46.28 |
| Price/Book(x) | 0 | 0 | 0 | 0 | 5.42 | 3.44 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.23 | 0.14 | 0.18 | 0.25 | 2.34 | 2.53 |
| EV/Core EBITDA(x) | 2.95 | 1.71 | 1.65 | 1.63 | 15.85 | 21.19 |
| Net Sales Growth(%) | 0 | 81.58 | 40.53 | 15.24 | 18.76 | 14.78 |
| EBIT Growth(%) | 0 | 98.82 | 109.84 | 55.38 | 8.37 | -12.08 |
| PAT Growth(%) | 0 | 214.58 | 144.91 | 46.84 | 17.17 | -31.82 |
| EPS Growth(%) | 0 | 191.73 | 124.1 | 55.41 | -13 | -35.64 |
| Debt/Equity(x) | 2.09 | 1.5 | 1.72 | 1.3 | 0.19 | 0.47 |
| Current Ratio(x) | 1.46 | 1.2 | 1.39 | 1.4 | 3.73 | 2.2 |
| Quick Ratio(x) | 0.91 | 0.76 | 0.87 | 0.86 | 2.32 | 1.5 |
| Interest Cover(x) | 2 | 4.26 | 6.07 | 5.17 | 7.94 | 4.1 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0.04 | 0.14 |
| # | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoter | 73.05 | 73.05 | 73.05 | 65.24 | 59.91 | 64.91 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0.02 | 0.21 |
| Public | 26.95 | 26.95 | 26.95 | 34.76 | 40.07 | 34.87 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoter | 1.02 | 1.02 | 1.02 | 1.02 | 0.93 | 1.01 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.38 | 0.38 | 0.38 | 0.54 | 0.62 | 0.54 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1.39 | 1.39 | 1.39 | 1.56 | 1.56 | 1.56 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
ChatGPT
Claude
Perplexity
